Skip to main content

Table 3 Unadjusted Cox regression for clinical outcomes according to liver fibrosis status

From: Association between liver fibrosis and thrombotic or bleeding events in acute coronary syndrome patients

Liver fibrosis staged by LFS

MACCE

All-cause death

Cardiac death

Myocardial infarction

Ischemic stroke

Major bleeding

TVR

Stent thrombosis

APRI

Low (N = 5639)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

Intermediate (N = 656)

1.1 (0.74–1.63)

1.12 (0.58–2.16)

1.62 (0.72–3.63)

1.67 (0.94–2.96)

1.06 (0.57–1.98)

0.91 (0.56–1.49)

1.13 (0.81–1.59)

1.29 (0.61–2.72)

p value

0.638

0.743

0.242

0.079

0.855

0.717

0.471

0.498

High (n = 91)

3.69 (2.06–6.6)

5.14 (2.24–11.8)

10.59 (4.47–25.09)

3.65 (1.33–9.99)

3.05 (1.12–8.3)

1.16 (0.37–3.65)

1.13 (0.47–2.74)

6.24 (2.49–15.61)

p value

< 0.001

< 0.001

< 0.001

0.012

0.029

0.794

0.784

< 0.001

AST/ALT ratio

Low (N = 3352)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

Intermediate (N = 2666)

1.31 (1.01–1.69)

1.94 (1.24–3.05)

1.61 (0.87–2.98)

1.4 (0.9–2.18)

1 (0.67–1.49)

1.17 (0.88–1.57)

0.85 (0.68–1.07)

1.13 (0.67–1.9)

p value

0.044

0.004

0.132

0.141

0.995

0.288

0.161

0.641

High (N = 368)

2.59 (1.74–3.85)

4.15 (2.21–7.8)

4.59 (2.06–10.21)

2.99 (1.56–5.74)

1.2 (0.55–2.64)

0.89 (0.45–1.75)

1.39 (0.93–2.08)

2.75 (1.31–5.8)

p value

< 0.001

< 0.001

< 0.001

0.001

0.647

0.726

0.11

0.008

Forns score

Low (N = 763)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

Intermediate (N = 4582)

1.59 (1.01–2.53)

1.95 (0.78–4.87)

2.69 (0.64–11.21)

1.39 (0.67–2.9)

1.76 (0.85–3.64)

1.34 (0.81–2.22)

0.92 (0.67–1.27)

1.52 (0.6–3.82)

p value

0.047

0.151

0.175

0.377

0.126

0.257

0.628

0.376

High (N = 1041)

1.91 (1.14–3.2)

4.46 (1.73–11.5)

5.94 (1.37–25.83)

1.49 (0.64–3.47)

1.22 (0.51–2.95)

1.68 (0.95–2.97)

0.77 (0.51–1.16)

2.39 (0.87–6.51)

p value

0.015

0.002

0.018

0.36

0.655

0.077

0.214

0.09

NFS

Low (N = 3109)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

Intermediate (N = 2842)

1.48 (1.13–1.94)

1.36 (0.86–2.15)

1.29 (0.67–2.46)

1.43 (0.91–2.25)

1.58 (1.04–2.4)

1.14 (0.84–1.53)

1.05 (0.84–1.31)

1.28 (0.74–2.21)

p value

0.004

0.192

0.445

0.124

0.034

0.401

0.688

0.377

High (N = 435)

3.43 (2.39–4.92)

4.14 (2.35–7.28)

5.5 (2.67–11.32)

3.06 (1.64–5.72)

2.75 (1.49–5.08)

1.27 (0.73–2.2)

1.16 (0.76–1.77)

4.2 (2.17–8.12)

p value

< 0.001

< 0.001

< 0.001

< 0.001

0.001

0.392

0.495

< 0.001

  1. LFS, liver fibrosis scores; MACCE, major adverse cardiac and cerebrovascular events; TVR, target vessel reconstruction; APRI, aspartate aminotransferase to platelet ratio index; AST/ALT ratio, aspartate aminotransferase to alanine aminotransferase ratio; NFS, nonalcoholic fatty liver disease fibrosis score